When the COVID-19 outbreak slammed the economy, it seemed like deal making in the biopharmaceutical industry would also slow down. However, the volume of deals hit an all-time high in 2020, with transactions using creative deal structures such as asset licensing to strategic R&D collaborations powering the growth.
A new KPMG report, Biopharmaceuticals deal trends: Competition for innovation overcomes economic headwinds, explains that the industry’s perpetual need to find innovative assets to generate future revenue will continue playing out in 2021 in the deal market. But picking the best opportunities among unproven targets amid rising valuations will be a challenge.
